Iloperidone (Fanapt): An FDA-approved treatment option for schizophrenia

P and T

Volumn 34, Issue 11, 2009, Pages

  Montes, Amy Barbara ^a   Rey, Jose A ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Atypical antipsychotic agent; Fanapt; Iloperidone; Schizophrenia; Serotonin dopamine receptor antagonist

Indexed keywords

FANAPT; HALOPERIDOL; ILOPERIDONE; PLACEBO; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

AKATHISIA; AREA UNDER THE CURVE; BLOOD PRESSURE; CHEMISTRY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HUMAN; MENTAL DISEASE; NAUSEA; NOSE CONGESTION; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT INTERVAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; SHORT SURVEY; SIDE EFFECT; SOMNOLENCE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; XEROSTOMIA;

EID: 73849126469     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (12)

1. World Health Organization. (WHO) Schizophrenia. Available at www.who.int/mental-health/management/schizophrenia/en. Accessed January 2, 2009.
2. Regier DA, Narrow WE, Rae DS, et al. The de facto U.S. mental and addictive disorders service system: Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993;50(2):85-94.
3. Terkelsen KG, Menikoff A. Measuring costs of schizophrenia: Implications for the post-institutional era in the U.S. Pharmacoeconomics 1995;8:199-222.
4. Geller JL. A historical perspective on the role of state hospitals viewed from the era of the 'revolving door.' Am J Psychiatry 1992;149:1526-1533.
5. Mueser KT, McGurk SR. Schizophrenia, Lancet 2004;363:2063-2072.
6. National Institute of Mental Health (NIMH). Schizophrenia. Available at: www.nimh.nih.gov/health/publications/schizophrenia/complete-index.shtml. Accessed January 2, 2009.
7. Fanapt (iloperidone), package insert. Rockville, MD: Vanda Pharmaceuticals, Inc.; May 2009.
8. Iloperidone. Chemogenomics Group. Available at: http://chembl.blogspot. com/2009/07/new-drug-approvals-pt-viii-iloperidone.html. Accessed July 27, 2009.
9. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: A pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008;25:S12-S19.
10. Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28:S20-S28.
11. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. J Clin Psychopharmacol 2008;28:S4-S11.
12. Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28:S29-S35.